Aurobindo Pharma acquires 80 percent stake in A1 Biochem Labs for USD 17 million

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹1525.80

prior close

₹1512.00

announcement price

After-mkt

timing

Nifty Midcap 150market-0.1%+0.5% vs market

Pharmaceuticals peers, median of 164sector-0.1%+0.5% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Midcap 150 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.1

15m

+1.4

30m

+1.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4-0.1+0.5-0.1+0.5

Next day

+1.7+1.0+0.6+0.5+1.1

+2.0+1.0+1.0+0.0+2.0

+4.0+1.8+2.1+0.6+3.4

+3.4+1.4+1.9-0.1+3.5

+3.6+1.9+1.6+0.2+3.4

+3.7+2.8+0.8+0.8+2.9

15d

+6.3+3.1+3.2+2.7+3.7

+5.5+3.2+2.3+1.4+4.1

+12.7-1.0+13.8+3.6+9.1

+4.2-8.3+12.5-4.2+8.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma subsidiary Apitoria Pharma will acquire 80 percent stake in A1 Biochem Labs (India) and A1 Biochem Labs LLC, USA at USD 17 million enterprise value, with USD 13.6 million for the 80 percent. A1 Biochem is a CRO with FY26 turnover of INR 1,024 million and EBITDA of INR 465 million. Expected to close in 90 to 120 days, creating an integrated CRDMO platform to complement Apitoria's API manufacturing. All cash, not a related party deal.

Likely market impact

Strengthens API lifecycle with CRDMO capability. Modest size at USD 17 million; adds a profitable, EBITDA-positive CRO to the group.